TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone
Authors:
Open Access
- 20 December 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 12, 485
Abstract
Dopaminergic neurons loss is one of the main pathological characters of Parkinson’s disease (PD), while no suitable neuroprotective agents have been in clinical use. Thyrotropin-releasing hormone (TRH) and its analogs protect neurons from ischemia and various cytotoxins, but whether the effect also applies in PD models remain unclear. Here, we showed that Taltirelin, a long-acting TRH analog, exhibited the neuroprotective effect in both cellular and animal models of PD. The in vitro study demonstrated that Taltirelin (5 μM) reduced the generation of reactive oxygen species (ROS) induced by MPP+ or rotenone, alleviated apoptosis and rescued the viability of SH-SY5Y cells and rat primary midbrain neurons. Interestingly, SH-SY5Y cells treated with Taltirelin also displayed lower level of p-tau (S396) and asparagine endopeptidase (AEP) cleavage products, tau N368 and α-synuclein N103 fragments, accompanied by a lower intracellular monoamine oxidase-B (MAO-B) activity. In the subacute MPTP-induced and chronic rotenone-induced PD mice models, we found Taltirelin (1 mg/kg) significantly improved the locomotor function and preserved dopaminergic neurons in the substantia nigra (SN). In accordance with the in vitro study, Taltirelin down-regulated the levels of p-tau (S396), p-α-synuclein (S129) tau N368 and α-synuclein N103 fragments in SN and striatum. Together, this study demonstrates that Taltirelin may exert neuroprotective effect via inhibiting MAO-B and reducing the oxidative stress and apoptosis, preventing AEP activation and its subsequent pathological cleavage of tau and α-synuclein, thus provides evidence for Taltirelin in protective treatment of PD.Keywords
This publication has 55 references indexed in Scilit:
- Distinct Effects of Rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on Cellular Bioenergetics and Cell DeathPLOS ONE, 2012
- Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortexNature Protocols, 2012
- Activation of extracellular signal-regulated kinase (ERK) and induction of mitogen-activated protein kinase phosphatase 1 (MKP-1) by perifused thyrotropin-releasing hormone (TRH) stimulation in rat pituitary GH3 cellsMolecular and Cellular Endocrinology, 2008
- Thyroid Function and the Risk of Alzheimer DiseaseThe Framingham StudyArchives of internal medicine (1960), 2008
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- The Thyrotropin-Releasing Hormone (TRH) Hypothesis of Homeostatic Regulation: Implications for TRH-Based TherapeuticsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Taltirelin Hydrate (TA‐0910): An Orally Active Thyrotropin‐Releasing Hormone Mimetic Agent with Multiple ActionsCNS Drug Reviews, 1998
- Effects of TA-0910, an orally active TRH analog, on the spinal reflex in spinal ratsNeuropharmacology, 1994
- A Summary of the Current Position of TRH in ALS TherapyAnnals of the New York Academy of Sciences, 1989
- Thyrotropin-Releasing Hormone Improves Neurologic Recovery after Spinal Trauma in CatsNew England Journal of Medicine, 1981